Kaye Biotech Inc. had the following equity account balances at December 31, 2016:

Preferred shares, $3.00, non-cumulative,
Authorized: 22,200 shares
Issued and outstanding: 6,100 shares	$	42,700
Common shares,
Authorized: Unlimited
Issued and outstanding: 90,500 shares		306,311
Retained earnings		45,000

On February 1, 2017, 6,100 preferred shares were issued at $8.80 each. The board of directors declared and paid the annual cash dividend on the preferred shares on June 30, 2017, and a 14% common share dividend was declared and distributed on the same day when the market price per common share was $4.75. On October 1, 2017, 22,200 common shares were issued at $4.89 each. Profit earned during 2017 was $419,800. Required: Using the information provided, prepare the statement of changes in equity for the year ended December 31, 2017. (Amounts to be deducted should be indicated by a minus sign.)